Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • Press releases
  • Investors & Media
    • Share information
    • Financial Reports
      • Annual reports
      • Interim reports
      • Year-end reports
    • Presentations
    • Media
      • Image library
      • Video library
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • Financial calendar
      • General meetings
  • Contact
    • Career
    • Business development
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllRegulatory posts
6 July 2021 Scandion Oncology announces that its President & CEO has bought 10,800 shares in Scandion Oncology Download Presentation Webcast Workbook
19 May 2021 Invitation to Scandion Oncology A/S audiocast on May 20, 2021 Download Presentation Webcast Workbook
4 May 2021 Scandion Oncology welcomes Mads Aaboe Jensen as VP for Business Development and Innovation Download Presentation Webcast Workbook
30 April 2021 2021 – a transformative year for Scandion Oncology Download Presentation Webcast Workbook
21 April 2021 Interview with COO and Head of R&D Operations Maj Hedtjärn in BioStock Download Presentation Webcast Workbook
18 March 2021 Invest Talks Download Presentation Webcast Workbook
20 February 2021 Great interest at our Year-end 2020 webcast Download Presentation Webcast Workbook
18 February 2021 Invitation to Scandion Oncology A/S live webcast on February 19, 2021 Download Presentation Webcast Workbook
4 February 2021 A great milestone Download Presentation Webcast Workbook
18 December 2020 Scandion Oncology tackles antioestrogen resistance Download Presentation Webcast Workbook
18 December 2020 Dansk lægemiddel ser ud til at bekæmpe resistens på tværs af kræftsygdomme Download Presentation Webcast Workbook
20 November 2020 +200 attendees joined our webcast today Download Presentation Webcast Workbook

Information types

Choose your information types.

Stay updated with news from Scandion Oncology

Subscribe below

Subscription successful. To activate the subscription, we request that you confirm your e-mail address. Do this by clicking on this link in the email we just sent you.
Subscription failed. Error:
  1. Frontpage

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science
  • Patents

Investors & Media

  • Investors & Media
  • Share information
  • Financial Reports
  • Presentations
  • Media
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us


Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Cookie settings | Disclaimer: Market data could be delayed. Delivered by Cision.

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all